Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MRCK34.SA
BuyMerck & Co., Inc. · Healthcare · United States · $384.9B · Avg Vol: $61K/d
79
StockRankGet insider-trade alerts
Q
55
V
42
M
77
P/E (TTM)
126.7x
ROE
7.0%
D/E
1.3x
Dividend %
1.5%
COMPANY DESCRIPTION
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair,...
FINANCIAL SUMMARY (BRL)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 308.6B | 312.9B | 334.0B | 338.4B | 3.1% | 346.5B | 349.5B | 365.9B | 4.0% |
| EPS (BRL) | 0.48 | 0.01 | 0.56 | 0.60 | 7.9% | 0.81 | — | — | — |
| Shares | 19.7B | 19.7B | 19.7B | 19.7B | 0.0% | 19.7B | — | — | — |
| Debt | 159.8B | 182.5B | 193.2B | 256.8B | 17.1% | 280.6B | — | — | — |
| Equity | 239.4B | 195.6B | 241.1B | 273.8B | 4.6% | — | — | — | — |
| Op CF | 99.4B | 67.7B | 111.7B | 85.7B | -4.8% | 103.9B | — | — | — |
| Inv CF | -25.8B | -73.3B | -40.3B | -71.5B | — | — | — | — | — |
| Fin CF | -47.5B | -25.0B | -36.6B | -10.0B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+21.6%
SMA 50SMA 200
Close
$18.53
RSI (14)
70.3
52W High
$19.48
From 52W High
1.0%
SCORE BREAKDOWN
Quality
55
ROIC
7.1%64.3
ROE
7.0%63.0
GP/Assets
36.9%75.4
Op. Margin
-0.2%34.5
FCF/Assets
11.7%89.2
Piotroski
431.8
Int. Cover
4.4x51.4
D/E Ratio
1.28x10.6
Current Ratio
1.32x20.9
Value
42
P/E (TTM)
126.7x5.9
EV/EBITDA
13.8x51.0
P/FCF
24.0x53.0
P/B
1.8x65.6
P/S
5.8x38.7
Div Yield
1.5%37.5
Momentum
77
52W High %
95%92.1
RS 6M
32%86.4
SMA 50/200
1.13x81.7
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$384.9B
P/E (Forward)
—
Gross Margin
75.9%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MRCK34.SA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MRCK34.SA | Merck & Co., Inc.(you) | $384.9B | 79 | Buy |
| RO.SW | Roche Holding AG | $372.5B | 86 | Strong Buy |
| NVS | Novartis AG | $292.3B | 82 | Strong Buy |
| AZN | AstraZeneca PLC | $252.3B | 77 | Buy |
| ABBV | AbbVie Inc. | $451.5B | 87 | Strong Buy |
| JNJ.DE | Johnson & Johnson | $651.4B | 80 | Strong Buy |
| GILD | Gilead Sciences, Inc. | $180.6B | 76 | Buy |
| AMGN | Amgen Inc. | $233.8B | 89 | Strong Buy |
| LLY | Eli Lilly and Company | $1.0T | 77 | Buy |
| NVO | Novo Nordisk A/S | $201.6B | 88 | Strong Buy |
Peer medians: ROE 1.9% · P/E 23.9x · Gross margin 52.1%